Navigation Links
Trius Therapeutics Awarded U.S. Department of Defense Contract to Develop Novel Antibiotics
Date:5/19/2010

SAN DIEGO, May 19 /PRNewswire/ -- Trius Therapeutics, Inc. today announced that it has been awarded a new four and a half year contract from the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense, for the development of novel antibiotics directed against gram-negative bacterial pathogens. Trius may receive up to $29.5 million in support of development efforts under the new DTRA contract, which is funded as part of DTRA's Transformational Medical Technologies Initiative (TMTI).  Pursuant to the contract, Trius will apply its proprietary Focused Antisense Screening Technology (FAST) discovery platform to identify the targets of antibacterial compounds from marine natural product libraries developed in the laboratory of Dr. William Fenical, Distinguished Professor of Oceanography at Scripps Institution of Oceanography at UC San Diego.  Trius will then apply its structure-based drug design and development capabilities in an effort to optimize promising antibacterial compounds for activity against gram-negative biodefense pathogens such as Yersinia pestis, Francisella tularensis and Burkholderia pseudomallei. Trius believes that these compounds will also be active against gram-negative pathogens involved in common hospital acquired infections.

This is the second government-funded research contract that has been awarded to Trius.  In September of 2008, Trius entered into a five-year contract with the National Institute of Allergies and Infectious Disease (NIAID), a component of the National Institutes of Health, under which Trius may receive up to $27.7 million.

About DTRA & TMTI

DTRA was founded in 1998 to integrate and focus the capabilities of the U.S. Department of Defense that address the weapons of mass destruction (WMD) threat. The mission of DTRA is to safeguard America and its allies from WMD (chemical, biological, radiological, nuclear and high yield explosives) by providing capabilities to reduce, eliminate and counter the threat, and mitigate its effects. Under DTRA, U.S. Department of Defense resources, expertise and capabilities are combined to ensure the United States remains ready and able to address the present and future WMD threats.  

TMTI was pioneered by the U.S. Department of Defense in 2006 to better prepare and protect the warfighter and the nation from emerging, genetically engineered and unknown biothreat agents.  It provides a novel response capability that spans the identification of pathogens to the development of medical countermeasures.

About Trius Therapeutics

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company's first product candidate, torezolid phosphate, is an IV and orally administered second generation oxazolidinone being developed for the treatment of serious gram-positive infections, including those caused by MRSA. In addition to the company's torezolid phosphate clinical program, it is currently conducting a preclinical program using its proprietary discovery platform to develop antibiotics to treat infections caused by bacteria of the gram-negative category. For more information, visit www.triusrx.com.

This press release contains forward-looking statements regarding Trius' planned activities under the DTRA and NIAID contracts, the aggregate amount of funding to be received under these contracts and the results of development efforts under these contracts, including the activity of any identified compounds. Actual results may differ materially from those in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing Trius, please see the risk factors described in the Company's Registration Statement on Form S-1 that was originally filed with the United States Securities and Exchange Commission on November 6, 2009, and the amendments thereto, including those factors discussed under the caption "Risk Factors" in such filings. Forward-looking statements speak only as of the date of this release, and Trius undertakes no obligation to update or revise these statements, except as may be required by law.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Trius Appoints Paul Truex to Board of Directors
2. Trius Awarded $28 Million Contract to Develop Novel Antibiotics
3. Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The ... is proud to add Target to its list of well-respected retailers. This list ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):